The UK Welcomes its First Open Innovation Campus for Drug Discovery and Development

February 14, 2012 By IdeaConnection
Image by Ambro
Image by Ambro

Britain’s first ever open innovation bioscience campus has now opened its many doors for business.

Focused on early-stage drug discovery and development, Stevenage Bioscience Catalyst will pioneer a unique and collaborative environment for companies of all shapes and sizes, including virtual and start-up firms.

They will be able to take advantage of high quality equipment, free e-journal use, laboratory and office space, and every other kind of state-of-the-art facility associated with global pharmaceutical companies. In other words, a range of offerings normally beyond small and medium-sized businesses.  There will also be plenty of scope for commercial opportunities.

Buildings in Phase 1 of the development consist of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space.

The aim is to create an atmosphere of open innovation that will put the UK at the forefront of worldwide biomedical discoveries.

The first residents are Aptiv Solutions, a company that provides drug and medical device development services.

“Everyone in the Stevenage Bioscience Catalyst team is delighted that we are open for business, and many thanks are due to everyone associated with the delivery of the facility,” said Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. “We are really pleased that our first occupant is a quality company like Aptiv Solutions, and are very encouraged by the discussions we are having with other potential tenants. “

The open innovation campus is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the East of EnglandDevelopment Agency.

Share on      
Next Post »

Add your Comment

[LOGIN FIRST] if you're already a member.

fields are required.

Note: Your name will appear at the bottom of your comment.